COCCIMETRICS: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM) Treated With Olorofim Plus Baseline Standard of Care (SOC) or With Placebo Plus Baseline SOC

The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated coccidioidomycosis (DCM).

开始日期2026-12-01

申办/合作机构

F2G Ltd.

[+1]

NCT07385638

/ Recruiting临床2期IIT

Phase 2, Open-label Evaluation of Olorofim in Early Coccidioidal Meningitis

This research study is being conducted to learn more about the use of olorofim in Coccidioidal (Cocci) meningitis, a rare but serious fungal infection that affects the brain and spinal cord. The study is exploratory, meaning that early information is being gathered to better understand the effectiveness of olorofim in coccidioidal meningitis in its early stages. The study plans to enroll approximately 10 to 12 participants who have been recently diagnosed-within the last 4 to 8 weeks-and who do not have a ventriculoperitoneal (VP) shunt, a medical device sometimes used to relieve pressure in the brain. Participants will be followed for approximately 6 months, during which health information will be collected to evaluate disease progression and response to treatment. Participants may have the opportunity to enroll in the olorofim Managed Access Program to continue treatment after completion of the study period.

开始日期2026-06-01

申办/合作机构

University of Arizona

[+1]

CTR20232748

/ Active, not recruiting临床1期

一项在健康中国人受试者中评估Olorofim单次口服给药的药代动力学和安全性的I期研究

本临床试验的主要目的是在中国健康受试者中评估Olorofim单次口服给药的PK，次要目的是在中国健康受试者中评估Olorofim单次口服给药的安全性和耐受性。

开始日期2023-11-09

申办/合作机构

盐野义有限公司

[+2]

100 项与 Olorofim 相关的临床结果

登录后查看更多信息

100 项与 Olorofim 相关的转化医学

登录后查看更多信息

100 项与 Olorofim 相关的专利（医药）

登录后查看更多信息

134

项与 Olorofim 相关的文献（医药）

2026-07-01·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Perspectives on Antimicrobial Agents: Fosmanogepix

Review

作者: Lamoth, Frederic

ABSTRACT:

Invasive fungal infections (IFIs) are associated with high mortality rates and pose important therapeutic challenges because of the limited number of antifungal drug classes, their toxicity, and the emergence of resistance. Novel first-in-class antifungal agents have been recently approved (ibrexafungerp) or are currently being tested in clinical trials and are available via expanded access programs (olorofim, fosmanogepix). Among them, fosmanogepix (a prodrug of manogepix) represents a promising future therapeutic option for many IFIs because of its broad-spectrum antifungal activity and its favorable pharmacologic properties, such as oral bioavailability, extended tissue distribution (including the central nervous system), a good safety profile, and the absence of relevant drug-drug interactions. Fosmanogepix may become an interesting alternative option for the treatment of invasive candidiasis due to multidrug-resistant isolates (e.g., Candidozyma auris ) or invasive aspergillosis due to azole-resistant Aspergillus spp. It also demonstrated very encouraging results for the treatment of invasive fusariosis and other refractory mold infections (e.g., scedosporiosis, lomentosporiosis). Novel gepix compounds have been developed and could make their niche in the future (e.g., APX2039, prodrug: APX2096, for cryptococcal meningitis, and APX2020, prodrug: APX2097, for coccidioidomycosis). This review discusses the future place of fosmanogepix in the antifungal armamentarium against IFIs.

2026-06-03·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim

Article

作者: Brüggemann, Roger ; Zinzi, Daniela ; Jones, Hannah M. ; Law, Derek ; Maertens, Johan ; Chen, Sharon C.-A. ; Upcott Gill, Rachel ; Cornelissen, Karen ; Rex, John H.

ABSTRACT:

Olorofim is a novel oral antifungal agent which selectively inhibits the fungal enzyme dihydroorotate dehydrogenase found in molds including Aspergillus , Scedosporium , Lomentospora , and Scopulariopsis and in dimorphic fungi such as Coccidioides . Based on in vitro studies, clinical pharmacology, and pharmacokinetic (PK) data from the Phase 2b FORMULA study (F901318/0032) as well as physiologically based PK (PBPK) modeling of drug interactions, the drug’s CYP-mediated interactions are now well understood. Olorofim is mainly metabolized by cytochrome P450 (CYP) CYP3A4, with minor contributions from CYP2C8 and CYP2C9. In vitro studies found that it inhibits CYP3A4, weakly inhibits CYP2D6 and CYP2C8, and weakly induces CYP1A2 and CYP2B6. Phase I studies confirm it is predominantly cleared by CYP3A4 and weakly inhibits CYP3A4. In the Phase 2b FORMULA study, co-administered sensitive CYP3A4 substrates required limited dose reductions when using olorofim. When used with strong CYP3A4 inhibitors, dual moderate inhibitors like fluconazole, or CYP3A4 inducers, dose adjustments were needed for olorofim. Physiologically based PK (PBPK) modeling predicted moderate effects with CYP3A4 inhibitors or inducers and negligible effects with weak CYP3A4 inhibitors or strong inhibitors of CYP2D6, CYP2C8, and CYP2C9. Overall, the drug’s interaction profile is predictable and manageable, making it a suitable candidate drug to use in treating patients with invasive fungal disease (IFD), who often require polypharmacy.

CLINICAL TRIALS:

This study is registered with ClinicalTrials.gov as NCT02680808 , NCT02730442 , NCT02737371 , NCT04171739 , NCT03340597 , and NCT03583164 .

2026-06-02·Open Forum Infectious Diseases

Invasive Fungal Sinusitis in Patients With Hematological Malignancies: A 20-Year Study From a Tertiary Academic US Hospital System

Article

作者: Villa, Inia Perez ; Bergmark, Regan W ; Liakos, Alexis D ; Strauch, Carolyn B ; Vedula, Rahul S ; Gupta, Simran ; Arbona-Haddad, Esther ; Sherman, Amy C ; Athni, Tejas S ; Tong, Alexandra ; Kovac, Victor ; Maxfield, Alice Z ; Aleissa, Muneerah M

Abstract:

Background:

Invasive fungal sinusitis (IFS) profoundly impacts individuals with hematological malignancies, with rapid progression and high mortality rates. In an evolving therapeutic landscape, outcomes for patients with hematological malignancies who develop IFS warrant further evaluation.

Methods:

We performed a descriptive case series and retrospective review of patients with hematologic malignancies who developed proven IFS (per European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria) between 2005 and 2024 at a tertiary academic center. Clinical data and outcomes were collected from electronic medical records. Statistical analyses included Fisher exact tests, t tests, or Wilcoxon rank-sum tests. Kaplan-Meier curves were used to estimate survival probability, and log-rank tests were compared across groups.

Results:

Thirty-one patients with confirmed IFS were identified. Most patients had acute myeloid leukemia (61.3%) and received cytotoxic chemotherapy (96.8%). Targeted oncologic therapies included BCL2 inhibitors (29.0%), FLT3 inhibitors (19.4%), antibody-based therapies (12.9%), BTK inhibitors (6.4%), and antibody–drug conjugates (6.4%). The most common fungal isolates were Aspergillus (22.6%), Fusarium (16.1%), and Rhizopus (9.7%). Amphotericin B (96.8%) and voriconazole (71.0%) were frequently used, and newer antifungals included isavuconazole (38.7%), olorofim (3.3%), and fosmanogepix (3.3%). Necrotic tissue (45.2%) and mucosal thickening (87.1%) were common on sinonasal endoscopy and computed tomography scan, respectively. Orbital (25.8%) and intracranial (9.7%) extension occurred in a minority. Most patients underwent functional endoscopic sinus surgery (80.6%). Serum fungal biomarkers were infrequently positive, with (1,3)-ß-D-glucan in 19.4% and galactomannan in 9.7%. Overall mortality was 71.0% at the end of the study period, with a median survival (interquartile range) of 101 (21–299) days. Mortality was 22.6% at 1 month, 25.8% at 2 months, 32.3% at 3 months, 41.9% at 6 months, 54.8% at 1 year, 58.1% at 2 years, and 64.5% at 3 years.

Conclusions:

Despite novel therapies and aggressive surgical interventions, patients with IFS had high mortality.

项与 Olorofim 相关的新闻（医药）

2026-06-25

·虹树下

医药日报6.25：NMPA四款FIC·GSK千亿收购

今日导读 🏛️ NMPA历史性时刻：6月22日一日批准4款全球首发创新药——双抗ADC、实体瘤CAR-T、狂犬病双抗、抗菌肽 💰 超级并购：GSK 106亿美元收购Nuvalent（精准肿瘤学）；礼来收购4E Therapeutics加码非阿片止痛 🤖 AI制药加速：赛诺菲×Owkin构建AI生物制药智能体；BMS部署Claude覆盖3万员工；字节拆分AI制药估值10亿美元 🔬 临床与审批：Ionis olezarsen获FDA批准（严重高甘油三酯血症）；武田zasocitinib头对头3期优效 🤖 AI 创新应用 🤝 战略合作赛诺菲×Owkin：五年期K Pro合作构建AI生物制药智能体 6月5日，赛诺菲与AI生物科技公司Owkin宣布多年合作，基于Owkin的K Pro AI科学家平台构建端到端AI生物制药智能体（biopharma agents），覆盖从早期靶点发现到临床试验决策的全流程。双方合作始于2021年9000万欧元肿瘤AI合作，此次扩展至免疫学等领域。赛诺菲旨在实现"生物人工智能超级智能"愿景，加速自动化药物研发最复杂环节。 🏢 企业级部署BMS携手Anthropic：Claude AI覆盖3万员工，打造药企"共享智能平台" 5月20日，百时美施贵宝（BMS）与Anthropic签署战略协议，将Claude AI部署为覆盖研发、临床开发、生产、商业化及企业职能的"共享智能平台"，赋能超3万名员工。部署聚焦三大方向：加速药物发现与开发、优化临床运营、提升商业决策。这是大型药企首次将前沿大模型作为企业级基础设施全面铺开，标志着AI从"实验工具"走向"核心生产力"。 🔥 独立融资字节跳动拆分AI制药业务：估值约10亿美元，首轮融资近2亿 6月中旬，字节跳动AI制药业务线正式启动拆分独立融资，核心团队、算法平台及在研管线整体注入新主体，落地上海。新公司估值约10亿美元，首轮融资近2亿美元，字节仍控股。同期，阿里健康发布战略级医学AI产品"氢离子"；京东健康AI医生"大为"用户突破50万；百度百图生科递交港交所上市申请；腾讯公开AI设计GLP-1减肥药专利——互联网巨头全面涌入AI制药赛道。 📊 行业趋势2026上半年Big Pharma AI交易井喷：从单点合作走向基础设施级部署 2026上半年，大型药企AI合作密集爆发：礼来与Chai Discovery、Noetik、Insilico Medicine（最高27.5亿美元）合作；辉瑞与Boltz合作抗体/小分子设计；武田与Iambic合作超17亿美元；Gilead扩展与Tempus AI合作。分析显示AI可将药物研发周期缩短40-50%，提升I期成功率。趋势核心：药企不再满足于"找分子"，而是在构建覆盖发现-临床-商业化的AI基础设施。🇺🇸 FDA 审批动态 ✅ 刚刚获批FDA批准Ionis TRYNGOLZA(olezarsen)：首个降低严重高甘油三酯血症胰腺炎风险药物 6月24日，FDA批准Ionis Pharmaceuticals的TRYNGOLZA（olezarsen）上市，作为饮食辅助疗法用于降低严重高甘油三酯血症（sHTG）患者的甘油三酯水平及急性胰腺炎风险。这是首个且唯一被批准同时降低甘油三酯和胰腺炎风险的疗法。Olezarsen为反义寡核苷酸（ASO）药物，此前已获优先审评。此次批准距PDUFA日（6/30）提前一周，凸显FDA审评效率。 📅 即将裁决6月底FDA冲刺周：Arcutis ZORYVE、Viridian veligrotug等多款待批 6月最后一周FDA将密集裁决：Arcutis ZORYVE乳膏0.3%（PDUFA 6/29）——拓展至2-5岁儿童斑块型银屑病，将成为该年龄段首个外用PDE4抑制剂；Viridian veligrotug（PDUFA 6/30）——甲状腺眼病BLA，THRIVE试验显著改善突眼；Lantheus LNTH-2501（6/29）——Ga-68 edotreotide PET显像剂。此前Ensitrelvir（口服新冠暴露后预防）和Cytisinicline（20年首个戒烟新药）已于6月16日和20日过PDUFA日。 GSK启动106亿美元收购Nuvalent要约：精准肿瘤学管线补强 6月24日，GSK正式启动对Nuvalent的106亿美元现金要约收购（$124/股，溢价40%），这是GSK十年来最大并购。Nuvalent核心资产zidesamtinib（ROS1抑制剂，PDUFA 9/18）和neladalkib（ALK抑制剂，PDUFA 11/27）均已获FDA突破性疗法认定，峰值销售潜力30-40亿美元。GSK新任CEO Luke Miels借此发力肿瘤赛道，应对Shingrix专利悬崖压力。💰 行业并购与交易 💊 非阿片止痛礼来收购4E Therapeutics：加码非阿片类慢性疼痛管线 6月16日，礼来宣布收购奥斯汀神经科学公司4E Therapeutics，聚焦下一代非阿片类慢性疼痛疗法。美国超5000万人受慢性疼痛困扰，阿片类诉讼压力催生巨大市场机遇。这是礼来近期M&A spree的延续——2026年至今已接连收购Curevo、LimmaTech等公司约38亿美元，礼来过去十年收购的biotech数量超过任何制药巨头。 🧠 精神神经大冢7亿美元完成收购Transcend Therapeutics，布局下一代精神神经治疗 6月12日，大冢制药（Otsuka）完成对Transcend Therapeutics的收购，首付7亿美元+最高5.25亿美元里程碑。Transcend的核心技术使用AI精准识别药物候选的适用患者群体，解决III期试验因患者队列错配而失败的老大难问题。大冢借此扩展下一代精神疾病治疗方案，呼应行业从"关系驱动"向"精准驱动"转型的趋势。 2026生物制药M&A破1060亿美元：专利悬崖倒逼Big Pharma"买管线" 截至6月，2026年生物制药M&A总额已达1060亿美元（201笔交易），全年有望创历史新高。近一个月内31笔交易合计超26亿美元，其中AI/计算平台类占16笔。核心驱动力：专利悬崖迫近、公开市场回暖、Big Pharma管线补充需求。叠加GSK 106亿美元收购Nuvalent、艾伯维109亿美元收购Apogee，超级并购节奏未见放缓。🔬 临床研究进展 🧬 头对头3期武田zasocitinib头对头3期优效：银屑病口服治疗标杆或将易主 6月11日，武田公布zasocitinib（TYK2抑制剂）对比deucravacitinib的头对头III期研究结果，在斑块型银屑病关键终点上实现统计学优效。Zasocitinib为每日一次口服药，此前已展现快速持久的皮损清除能力。该结果有望重新定义口服银屑病治疗标准，对BMS的deucravacitinib（Sotyktu）构成直接竞争威胁。 🦠 抗真菌F2G/盐野义olorofim全球3期OASIS研究阳性：全新机制抗真菌药问世 6月18日，F2G与盐野义宣布口服olorofim对比AmBisome序贯标准疗法治疗侵袭性曲霉病的全球III期OASIS研究取得积极顶线结果。Olorofim属于全新orotomide类抗真菌药，靶向嘧啶生物合成途径，与现有三唑类/棘白菌素类无交叉耐药。数据将递交FDA（F2G）和EMA（盐野义），有望成为20年来首个新机制口服抗真菌药。 Definium DT120抑郁症3期成功：速效微剂量LSD衍生物呼之欲出 6月22日，Definium Therapeutics公布DT120（lysergide ODT 100µg口崩片）治疗重度抑郁症的EMERGE 3期试验达主要终点，股价当日飙升近50%。该药为微剂量LSD衍生物，具有起效快的差异化优势，若获批将成为抑郁症治疗的重要新选择，挑战传统SSRI类药物的统治地位。🏛️ 国内监管与政策 🏆 历史性突破NMPA一日批准4款全球首发创新药：中国创新药进入"全球首发"收获期 6月22日，NMPA连发五条公告，一日内密集批准4款全球首款中国原创1类创新药：①伦康依隆妥单抗（百利天恒BL-B01D1）——全球首款EGFR/HER3双抗ADC，用于复发/转移性鼻咽癌，III期cORR 54.6% vs 27.0%，海外权益已授权BMS（84亿美元）；②舒瑞基奥仑赛（科济药业CT041）——全球首款实体瘤CAR-T，靶向CLDN18.2治疗晚期胃癌，mPFS翻倍（3.25 vs 1.77个月）；③斯乐韦米单抗（智翔金泰）——全球首款狂犬病双特异性抗体，用于暴露后被动免疫；④培来加南喷雾剂（普莱医药）——全球首款加南类抗菌肽，用于烧烫伤创面感染。互联网巨头全面涌入AI制药：字节、百度、阿里、腾讯、京东各出奇招 6月以来，中国互联网巨头AI制药布局集中浮出水面：字节跳动拆分AI制药业务（估值10亿美元）；百度百图生科秘密递交港交所上市申请；阿里健康发布战略级医学AI产品"氢离子"；京东健康AI医生"大为"用户突破50万；腾讯公开AI设计GLP-1减肥药专利。行业判断：中国AI制药正从"跟跑"转向"部分领域领跑"，成为全球合作中的关键一极。 2026医保目录调整申报已完成，创新药准入持续提速国家医保局5月31日发布《2026年药品目录调整工作方案》，首次将商业健康保险创新药品目录纳入联动调整。6月1日-10日已完成网上申报。同步，第十二批国家药品集采已明确年内开展。政策趋向：鼓励真创新、淘汰伪创新，医保准入向创新药倾斜与集采常态化双轨并行。🧬 生物技术与研究前沿 🧪 AI设计疫苗全球首个AI设计通用冠状病毒疫苗通过I期人体试验 6月5日，剑桥大学及衍生企业DIOSynVax在《感染杂志》发表全球首个完全由AI设计的泛沙贝科冠状病毒疫苗pEVAC-PS的I期临床试验结果：疫苗安全、耐受性良好，并能产生针对多种冠状病毒的免疫反应。该疫苗由AI计算平台设计靶点抗原，标志着AI从药物发现扩展至疫苗设计领域，为下一代广谱疫苗开发开辟新路径。 Intellia体内CRISPR疗法滚动上市申请进行中，有望2027年上市 Intellia Therapeutics的CRISPR基因编辑疗法在关键临床试验中取得成功，已向FDA启动滚动式递交上市申请（rolling BLA）。若获批计划2027年上市，这将是继CASGEVY后又一走向市场的CRISPR疗法。结合此前荷兰团队开发的能精准辨别肿瘤DNA的CRISPR变体、以及佛罗里达大学DNA引导CRISPR系统，基因编辑技术正进入快速迭代和临床转化期。⚡ 今日速览 🏛️ NMPA：一日批准4款全球首发——双抗ADC、实体瘤CAR-T、狂犬病双抗、抗菌肽 ✅ FDA：Ionis olezarsen获批（严重高甘油三酯血症） 💰 并购：GSK 106亿美元收购Nuvalent（精准肿瘤学） 💊 并购：礼来收购4E Therapeutics（非阿片止痛）；大冢7亿美元收购Transcend 🤖 AI：赛诺菲×Owkin AI智能体；BMS部署Claude覆盖3万人；字节拆分AI制药 🔬 临床：武田zasocitinib头对头3期优效；F2G olorofim抗真菌3期阳性 🧬 前沿：AI设计通用冠状病毒疫苗通过I期人体试验 📢 声明以上内容整理自公开信息，仅供参考，不构成投资建议。数据来源包括FDA官网、NMPA官网、Nature、BioSpace、FierceBiotech、RTTNews、药时代、腾讯新闻、新浪财经、InforCapital、LevelFields等。如有疏漏，欢迎指正。

2026-06-24

·北京医学感染与传染研究

抗菌化疗杂志81卷 1-6期、增刊1期（2026年6月24日更新）

Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期 https://academic.oup.com/jac/issue 50th Anniversary Collection（50周年纪念合集） Review（综述） 1 Artificial intelligence for improving decision-making in bacterial infection management: a narrative review 人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述 Anisia Talianu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470 Reviews（综述） 2 Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America 耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现 Lillian Rose Giarratana and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340 3 Azithromycin resistance in non-typhoidal Salmonella: a review 非伤寒沙门氏菌对阿奇霉素的耐药性：综述 Zhe Zhu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341 4 Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications 抗生素药效动力学：从最低抑菌浓度到高级指标及其应用 Malin Andersson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374 5 Progress in the study of drug resistance mechanism of Bacillus cereus 蜡样芽孢杆菌耐药机制研究进展 Yuhang Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399 6 The curious constraints on clofazimine 氯法齐明的奇特限制 Maple Goh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430 7 Antiplasmid systems: a novel strategy to combat antibiotic resistance 抗质粒系统：对抗抗生素耐药性的新策略 Mohd Asim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472 Systematic Review（系统综述） 8 Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes 欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述 Priya Shastri and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407 9 Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method 用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述 Najla Alabdulkarim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446 Virtual Roundtable（虚拟圆桌会议） 10 Procalcitonin in the management of lower respiratory tract infection and sepsis 降钙素原在下呼吸道感染和败血症治疗中的应用 Ramy H Elshaboury and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298 Original Research（论著） 11 Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients 来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估 Chrisoula Tahtsidou and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427 12 In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis 体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435 13 Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study 评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究 Nicolas Grégoire and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381 14 Real-life use of isavuconazole in Spanish children and adolescents 西班牙儿童和青少年中艾沙康唑的实际使用情况 Natalia Mendoza-Palomar and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394 15 No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis 基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号 Slobodan M Jankovic and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395 16 Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet 成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较 Nirjan Bhattarai and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396 17 Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究 Beibei Liang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398 18 Differences in prescription for impetigo and cellulitis across years in three European countries 三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异 Thomas Bettuzzi and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400 19 β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit 重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度 Karolina Liljedahl Prytz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401 20 Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system 在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较 Jelmer Raaijmakers and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402 21 Identification of antimicrobial resistance genes in Escherichia coli through network diffusion 通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因 Anis Mansouri and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404 22 Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease 依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估 Sanjay Singh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405 23 The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法 Malin Andersson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406 24 Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction 解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系 Maria Montaner and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408 25 Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge 不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战 Ana C Almeida-Santos and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409 26 Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study 在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果 Romain Palich and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410 27 HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda 乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联 Anne Kapaata and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411 28 Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States 美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况 Sarah C J Jorgensen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412 29 Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies 奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究 Saskia E Mudde and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413 30 Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023) 后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023） Mekki F Bensaci and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414 31 Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions 慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联 Gabriel P E Silveira and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416 32 Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis 博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析 Biao Tang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418 33 Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation) 基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释） Yinzheng Zhong and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419 34 Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights 印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察 Shristi Verma and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420 35 Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations 减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示 Yeleen Fromage and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421 36 Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates 基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性 Reham Mostafa and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422 37 Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing 危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药 Sonya Tang Girdwood and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423 38 Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients 达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量 W Töpfer and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424 39 Notable transmitted HIV drug resistance among people who inject drugs in Pakistan 巴基斯坦注射毒品人群中显著传播的HIV耐药性 Stephanie Melnychuk and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425 40 Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium 协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性 Ahmed Ashrin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426 41 Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model 中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究 Panagiota-Christina Georgiou and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431 42 Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp. 非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗 Clayton F Hausberger and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432 43 Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus 阿普拉霉素及其组合对脓肿分枝杆菌的增强活性 Yanqin Huang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433 44 Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene 印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制 Dipika Shaw and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434 45 Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases 鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者 Delphine Girlich and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436 46 Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征 Pengpeng Min and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437 47 Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients 血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性 Thornthun Ueaphongsukkit and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439 48 In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales 头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性 Marion Dutkiewicz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440 49 In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates 舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效 Kirby Patterson-Fahy and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441 50 Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate 利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性 Ruonan Zhao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442 51 Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life? 重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？ Manon Launay and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443 52 National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing 哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析 Ernesto Martínez-Buitrago and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444 53 A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens 基于模型的含固定剂量多替拉韦方案减量策略比较 Laura Dickinson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445 54 Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE) 住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究） Pjotr P Temme and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447 55 Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes 奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究 Jose Valdes Ledesma and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448 56 Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study 采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究 Sacha Kuil and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451 57 High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24 2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高 Josefine Ahlstrand and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452 58 Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable 尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定 Cathia Soulie and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454 59 Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications 延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析 Hannah S Pauw and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455 60 β-Lactam dosing in critically ill children: predictors for target non-attainment 危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素 Stef Schouwenburg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457 61 Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis 实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况 Barbara Alexander and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461 62 In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes 携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选 Otávio Hallal Ferreira Raro and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462 63 Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input 预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联 María M Montero and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464 64 A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations 全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局 Efi Mantzourani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466 65 Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus 提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试 Henriëtte M Meliefste and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468 Research Letters（研究快报） 66 Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany 德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731 Henrike Krüger-Haker and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336 67 Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report 厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告 Monica Melchio and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347 68 Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients 来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加 Jose F Camargo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348 69 Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring 达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用 Ambra Barco and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365 70 Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report 血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告 Kohei Hasegawa and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373 71 Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes 使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析 Antoine Hérault and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390 72 Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy 产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播 Gloria D’Achille and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397 73 Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry 来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据 Tommaso Clemente and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415 74 Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker 猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况 Gi Yong Lee and Soo-Jin Yang Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428 75 Importance of reviewing the package insert from gradient strip manufacturers 梯度扩散法药敏纸片生产商说明书审阅的重要性 Mandy Wootton and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429 76 One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene 一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成 Christopher J Harmer and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450 77 Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis 接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿 Cristina Gómez-Ayerbe and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456 78 In vitro activity of gepotidacin against Chlamydia trachomatis 吉皮达星对沙眼衣原体的体外活性 Arabella Touati and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460 Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期 https://academic.oup.com/jac/issue Viewpoints（观点） 1 Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? 长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？ Aleece MacPhail and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471 2 Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies 靶向治疗时代急性白血病抗真菌预防的重新定义 Marcio Nucci and Johan Maertens Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010 Reviews（综述） 3 Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae 替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展 Meilin Wu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504 4 Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations 两性霉素B脂质体与肾脏安全性：证据回顾及临床考量 Johan Maertens and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473 5 Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era 奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略 Keiji Okinaka and Joshua T Schiffer Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489 Systematic Reviews（系统综述） 6 Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis 吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析 Taha Ibrahim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469 7 The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review 产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述 Bruna Abdul Ahad Saad and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476 8 A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae 决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析 Sambit Kumar Dwibedy and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503 9 Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review 促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述 Hester H Stoorvogel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490 Original Research（论著） 10 Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics 头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究 M B D Nielsen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487 11 Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients 体外膜肺氧合模式对危重患者伏立康唑暴露的影响 Xinrui Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501 12 Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants 基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案 Dustin Huynh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449 13 Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis 铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析 Karolina Anna Mielko-Niziałek and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453 14 In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates 头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性 Carlo Tascini and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467 15 Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands 荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况 Patrick D J Sturm and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475 16 Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant Acinetobacter baumannii 模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用 Xiaonan Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477 17 Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case 加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例 Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478 18 The effect of intrauterine exposure to aminoglycosides on neonatal hearing 宫内暴露于氨基糖苷类抗生素对新生儿听力的影响 Daniel Leshin-Carmel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483 19 Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies 头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略 Jiaju Zhuo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495 20 Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints 采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果 Xinying Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502 21 Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis 肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况 Pascal Chavanet and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474 22 Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi 用于检测广泛耐药伤寒沙门菌的快速分子诊断技术 Emma L Sweeney and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481 23 Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22 性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析 Deepshikha Batheja and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002 24 Real-world evaluation of isavuconazole in children with cancer 伊沙康唑在儿童癌症患者中的现实应用评估 Janine Nijhuis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485 25 Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study 加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究 Joseph Elikem Efui Acolatse and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003 26 Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan 台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性 Guan-Jhou Chen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488 27 In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates 吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性 Michelle Jayne Cole and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001 28 A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database 基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析 Ye-Lei Zhao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006 29 Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis 基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用 Andres Mazariegos Herrera and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014 30 evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology 运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架 Ryan A Hamilton and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438 31 First characterization of insertions in the HIV-1 integrase-coding region from people with HIV 首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析 Nhat Quang Tu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491 32 Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae 开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法 Caitlin N Daniels and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493 33 Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats 新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究 Hitesh A Kadu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008 34 Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents 欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究 Marika A de Hoop-Sommen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463 35 Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study 门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究 R C Wilson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484 36 Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy 性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响 Maria Vittoria Cossu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024 37 Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock 头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学 Julius J Schmidt and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496 38 Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa 了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制 Yoshinori Yamano and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004 39 Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD 基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响 Yao Liu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500 40 Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia 评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498 Research Letters（研究快讯） 41 False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report 不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告 J Kimmerlin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459 42 Proposal for the nomenclature of tmexCD-toprJ-like gene clusters 关于tmexCD-toprJ样基因簇命名的建议 Chengzhen Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482 43 IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合 Yan Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018 Letter to the Editor（致编辑的信） 44 Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes 对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论 Gwénola Marais and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465 45 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply 意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027 ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家） 46 Acknowledgement of Referees 鸣谢审稿专家 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417 CORRECTION（更正） 47 Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial 更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492 Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期 https://academic.oup.com/jac/issue REVIEW（综述） 1 Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations 缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架 Josep M Llibre and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052 2 Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation 成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍 Daniel B Chastain and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055 3 Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future 细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案 Daisuke Fukuda and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054 4 Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions 应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向 Robiul Islam and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064 SYSTEMATIC REVIEW（系统综述） 5 Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis 耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析 Stamatis Karakonstantis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037 Original Research（论著） 6 The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting 三级门诊常规剂量口服环丙沙星对患者QT间期的影响 Weber Liu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020 7 Bictegravir concentrations in breastmilk of healthy, lactating women without HIV 未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度 L C van der Wekken-Pas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022 8 Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study 从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究 Anastasia Saade and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021 9 Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study 万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究 Tomoyuki Ishigo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012 10 Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用 Jolieke A T van Osch and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033 11 Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies 体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响 Jie Gao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032 12 Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease 用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究 Seef Abdalla and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019 13 Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24 2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总 Robyn Thorington and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007 14 Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool 使用新型决策支持工具改进围手术期预防性抗生素处方 Mark Mcintyre and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015 15 Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study 针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究 Ángel Rodríguez-Villodres and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034 16 Impact of eravacycline on fibrinogen 依拉环素对纤维蛋白原的影响 Emily Stevenson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030 17 Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients 原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究 Milo Gatti and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009 18 Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates 从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性 Natsuki Yamanaka and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017 19 In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm 双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究 Si-Ho Kim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031 20 LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效 Xing Xia and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036 21 HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用 Giuseppe Lapadula and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045 22 Pharmacokinetics of colistin in adult critically ill patients in South Africa 南非成人危重症患者中多黏菌素的药代动力学研究 Veshni Pillay-Fuentes Lorente and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011 23 Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24) 2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测 Su Chen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016 24 Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study 短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究 Beatriz Borjabad and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040 25 Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials 美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析 Priscilla Y Hsue and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005 26 Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection 采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究 Thomas Lin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039 27 Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries 撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式 Abubaker Ibrahim Elbur and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497 28 Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study 老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究 Arnaud De Clercq and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048 29 Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations 基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案 Wenyan Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499 30 Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study 快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究 Salvatore Rotundo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056 31 Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK 与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析 Laura Ciaccio and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049 32 Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study 英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究 Stephen Hughes and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038 33 Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study 糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究 Win Min Han and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053 34 A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025 基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析 Connor Frey and Parham Elmi Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060 35 Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs 体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据 Huifang Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063 36 Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes 在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果 Laura Pezzati and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035 37 A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa 用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型 Yali Fan and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061 38 Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery 微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果 Quentin Saint-Genis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071 39 Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers 伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型 Hui Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065 40 Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study 利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究 Hester H Stoorvogel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068 41 Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort 当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据 Katja Wallander and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067 42 Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China 治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究 Litai Qin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073 RESEARCH LETTER（研究快讯） 43 Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy 嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎 Yan Feng and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041 44 The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib 糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击” Bianca Monti and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028 45 Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子 Francesca Romana Massacci and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046 46 HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库 Rémi Rouget and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050 47 An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data 一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告 Pierangelo Chinello and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013 48 Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales 碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法 Hippolyte De Swardt and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066 49 Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence 头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战 Stephen Hughes and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051 LETTERS TO THE EDITOR（致编辑的信） 50 Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Chris Kenyon Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025 51 Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply 来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权 Jose F Camargo and Anthony D Anderson Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043 52 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply 意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026 53 Comment on: Artificial intelligence for improving decision-making in bacterial infection management 述评：人工智能在细菌感染管理决策中的优化作用 Daniele Roberto Giacobbe Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078 CORRECTION（更正） 54 Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study 更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494 55 Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing 更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057 Journal of Antimicrobial Chemotherapy Volume 81, Issue 4抗菌化疗杂志81卷 4期 https://academic.oup.com/jac/issue 50TH ANNIVERSARY COLLECTION（50周年纪念合集） GARROD LECTURE（加罗德讲座） 1 Garrod lecture: achieving the UNGA AMR mortality reduction goals 加罗德讲座：实现联合国大会抗菌药物耐药性死亡率降低目标 Ramanan Laxminarayan Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag082, https://doi.org/10.1093/jac/dkag082 REVIEW（综述） 2 25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat? 侵袭性曲霉病血液病患者25年死亡率改善情况：这种改善能否持续，还是正受到威胁？ Johan A Maertens and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag077, https://doi.org/10.1093/jac/dkag077 3 A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit 针对锥虫病的从高质量潜在客户和药物开发候选者出发的战略发现路线图。第二部分：从分子到确证活性分子 Sarah Hendrickx and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag110, https://doi.org/10.1093/jac/dkag110 VIRTUAL ROUNDTABLE（虚拟圆桌会议） 4 Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence 侵袭性霉菌病的诊断与危险因素——根据现有证据指导抗真菌治疗的圆桌讨论 Ana Alastruey-Izqueirdo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag062, https://doi.org/10.1093/jac/dkag062 EDITORIALS, MESSAGES FROM THE OUTGOING AND INCOMING EDITORS-IN-CHIEF（社论、离任与就任主编寄语） 5 Message from the incoming Editor-in-Chief of JAC 《抗菌化疗杂志》就任主编寄语 Monica A Slavin Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf479, https://doi.org/10.1093/jac/dkaf479 6 Message from the outgoing Editor-in-Chief 离任主编寄语 J Peter Donnelly Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf480, https://doi.org/10.1093/jac/dkaf480 REVIEW（综述） 7 Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems 用于药代动力学和药效学研究的实验性生物膜模型：连接体外、离体和体内系统 Stephanie Supparitsch and Markus Zeitlinger Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag091, https://doi.org/10.1093/jac/dkag091 8 Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics 感染性坏死性胰腺炎的抗菌治疗：微生物学、抗菌药物耐药性及药代动力学 Hannah S Pauw and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag092, https://doi.org/10.1093/jac/dkag092 9 Continuous linezolid infusion: the new way to dose, the old risks to fear 持续输注利奈唑胺：新的给药方式，仍需警惕旧有风险 Daniel Muñoz-Pichuante and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag100, https://doi.org/10.1093/jac/dkag100 10 Alignment of national standard treatment guidelines with WHO AWaRe recommendations for adult primary care infectious diseases: implications for antimicrobial stewardship 将国家标准治疗指南与世卫组织（WHO）针对成人初级保健传染病的“慎用、监测、备用”（AWaRe）推荐意见相统一：对抗菌药物管理的影响 Huda Arooj and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag099, https://doi.org/10.1093/jac/dkag099 SYSTEMATIC REVIEW（系统综述） 11 Healthcare providers’ experiences in caring for MDRO carriers with a focus on the moral dimensions of care: a systematic review 医疗服务提供者护理多重耐药菌（MDRO）携带者的经历——聚焦护理中的道德维度：一项系统综述 Carlijn Damsté and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag059, https://doi.org/10.1093/jac/dkag059 12 Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review 奥利他万星药代动力学/药效学目标的外推用以指导治疗药物监测：一项系统综述 Giammarco Baiardi and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag117, https://doi.org/10.1093/jac/dkag117 ORIGINAL RESEARCH（论著） 13 Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia 超越血浆：明确上皮衬里液暴露谱对肺炎治疗的转化价值 Yakun Fu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf458, https://doi.org/10.1093/jac/dkaf458 14 Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study 负荷剂量β-内酰胺类药物治疗非重症监护病房患者产KPC肺炎克雷伯菌血流感染的疗效影响：一项现实研究 Luisa Frallonardo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag087, https://doi.org/10.1093/jac/dkag087 15 Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro 雷扎芬净在体外对真菌生物膜表现出抗生物膜特性 Hafsa Abduljalil and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag058, https://doi.org/10.1093/jac/dkag058 16 Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital 万古霉素耐药性可预测屎肠球菌血流感染患者死亡率增加：意大利一家大型三级医院六年来的经验 Lucia Graziani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag069, https://doi.org/10.1093/jac/dkag069 17 Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database 氟喹诺酮类药物与惊恐发作风险：基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库中个体病例安全报告的系统综述和比例失衡分析 Keeirah Hiertika Raguram and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag083, https://doi.org/10.1093/jac/dkag083 18 Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study 在接受口腔癌切除术的患者中，采用随机临床微透析研究，探究头孢呋辛在面动脉肌黏膜瓣、颊黏膜下层、皮下组织和血浆中的浓度（团注或持续输注后） Johanne Ravn Hansen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag085, https://doi.org/10.1093/jac/dkag085 19 Infection point of care tests bridge the experience gap of antibiotic STOP decisions: clinicians versus students 感染即时检测可弥补抗生素停药决策方面的经验差距：临床医生与学生对比 Archit Singhal and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf486, https://doi.org/10.1093/jac/dkaf486 20 Functional analysis of a novel macrolide–lincosamide resistance gene erm(57) in Cutibacterium avidum 痤疮丙酸杆菌中一种新型大环内酯 - 林可酰胺类耐药基因erm(57)的功能分析 Juri Koizumi and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag029, https://doi.org/10.1093/jac/dkag029 21 HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial 莱索托和坦桑尼亚病毒血症儿童及青少年中的HIV耐药性：GIVE MOVE试验的嵌套分析 Christof Manuel Schönenberger and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag070, https://doi.org/10.1093/jac/dkag070 22 Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients 在儿科重症监护患者回顾性队列中识别和评估儿科头孢吡肟诱导的神经毒性 Kathryn Pavia and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag075, https://doi.org/10.1093/jac/dkag075 23 Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database 整合酶抑制剂和非核苷类逆转录酶抑制剂相关不良事件的优先级排序：基于FAERS数据库数据的比例失衡分析 Gao-yang Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag074, https://doi.org/10.1093/jac/dkag074 24 Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020 自2020年以来西班牙多队列分析中，儿童、青少年及青年时期感染HIV者的临床及免疫病毒学状态 Laura Tarancon-Diez and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag079, https://doi.org/10.1093/jac/dkag079 25 Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study 接受体外膜肺氧合治疗的危重成年患者美罗培南的群体药代动力学——一项ASAP ECMO研究 Mohd H Abdul–Aziz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag090, https://doi.org/10.1093/jac/dkag090 26 Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing 2022年至2024年意大利流行HIV-1亚型间传播耐药性的评估：通过下一代测序技术进行的精细分析 Daniele Armenia and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag084, https://doi.org/10.1093/jac/dkag084 27 Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter 耐药增强型变异体RE-CmeABC中氟苯尼考外排泵通道在弯曲菌中的特性研究 Hong Yao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag047, https://doi.org/10.1093/jac/dkag047 28 Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity 鲍曼不动杆菌中黏菌素异质性耐药的基因组特征：lpxD缺失及附带敏感性的证据 Banu Sancak and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag076, https://doi.org/10.1093/jac/dkag076 29 Sustaining stewardship: longitudinal evaluation of an integrated antimicrobial programme in the ICU 持续管理：重症监护室（ICU）综合抗菌药物管理项目的纵向评估 Ashmitha Thomas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag086, https://doi.org/10.1093/jac/dkag086 30 Global dissemination of optrA-mediated linezolid resistance in enterococci 利奈唑胺耐药性基因optrA介导的肠球菌在全球的传播 Jia Qi Beh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag089, https://doi.org/10.1093/jac/dkag089 31 Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing 利用肠外头孢菌素敏感性试验预测大肠杆菌血培养分离株对口服头孢菌素的敏感性 Tho H Pham and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag093, https://doi.org/10.1093/jac/dkag093 32 The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models 在小鼠大腿和肺部感染模型中多粘菌素B对鲍曼不动杆菌的药效动力学研究 Sanne van den Berg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag097, https://doi.org/10.1093/jac/dkag097 33 Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations 关于tmexCD-toprJ的基因组见解：质粒介导的细菌群体进化、传播与多样性 Lilan Wan and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag107, https://doi.org/10.1093/jac/dkag107 34 Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study 初治患者基线耐药突变与多替拉韦病毒学应答：一项多中心下一代测序（NGS）研究 Alexy Inciarte and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag080, https://doi.org/10.1093/jac/dkag080 35 Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study 非洲非B型HIV-1毒株中与多替拉韦（DTG）基因型耐药相关的新型整合酶突变：DTG耐药研究 Nuri Han and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag088, https://doi.org/10.1093/jac/dkag088 36 Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model 体外宫颈阴道HIV预防模型的药理学评估 Lindsey B Collins and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag103, https://doi.org/10.1093/jac/dkag103 37 The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions NOSO-502药效学指数的幅度：病原体清除、耐药性出现和人体剂量预测 Sanne van den Berg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag106, https://doi.org/10.1093/jac/dkag106 38 Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales? 替莫西林：治疗第三代头孢菌素耐药肠杆菌目引起的骨关节感染的一种替代疗法？ Louise Piquart and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag105, https://doi.org/10.1093/jac/dkag105 39 Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors 产金属β-内酰胺酶的肠杆菌科细菌：含氰化物的外排泵抑制剂作为潜在的双活性抑制剂 Otávio Hallal Ferreira Raro and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag122, https://doi.org/10.1093/jac/dkag122 40 Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli 外膜囊泡传递blaNDM-5并包装金属β-内酰胺酶以促进大肠杆菌的抗生素耐药性 Ting-Yin Lu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag123, https://doi.org/10.1093/jac/dkag123 41 Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin 一株鸡源ST412-K57多粘菌素耐药高毒力肺炎克雷伯菌的特征分析 Qiu Xu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag114, https://doi.org/10.1093/jac/dkag114 42 Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study 奥罗芬明与唑类抗真菌药联合使用：2期挽救治疗研究结果 Johan Maertens and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag118, https://doi.org/10.1093/jac/dkag118 RESEARCH LETTER（研究快讯） 43 Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion 母体病毒得到抑制，婴儿仍发生HIV传播：一例断奶后血清转阳病例 Shadia Nakalema and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag072, https://doi.org/10.1093/jac/dkag072 44 Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy 危重患者中尿抗原阴性军团菌肺炎：系统分子检测在优化抗菌治疗中的价值 Livia Foglia Manzillo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag101, https://doi.org/10.1093/jac/dkag101 45 Contribution of SHV-1 overexpression to carbapenem resistance in a Klebsiella pneumoniae clinical isolate SHV-1过表达对某株肺炎克雷伯菌临床分离株碳青霉烯类抗生素耐药性的影响 Céline Plainvert and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag108, https://doi.org/10.1093/jac/dkag108 LETTER TO THE EDITOR（致编辑的信） 46 Comment on: Possible increased risk of Epstein–Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients 评论：接受莱特莫韦治疗的造血细胞移植受者中，EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加 Jan Styczynski Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag042, https://doi.org/10.1093/jac/dkag042 47 Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis users in Milan, Italy 评论：意大利米兰地区使用多西环素暴露后预防措施人群中针对细菌性性传播感染的抗菌药物使用情况 Luca Bortolani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag023, https://doi.org/10.1093/jac/dkag023 48 Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes—right to reply 使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净药物治疗监测的回顾性分析——答复权 Antoine Hérault and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag095, https://doi.org/10.1093/jac/dkag095 49 Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study 评论：替莫西林与其他静脉注射β-内酰胺类抗生素治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究 Shanshan Ru and Yingzhe Zhang Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag096, https://doi.org/10.1093/jac/dkag096 50 Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? 评论：长效糖肽类抗生素：对于最需要它们的患者，获取的障碍是什么，如何克服？ Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag102, https://doi.org/10.1093/jac/dkag102 51 Comment on ‘Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes’ 评论：“对使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净的药理学治疗监测的回顾性分析” Julien Massol and Frédéric Baud Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag094, https://doi.org/10.1093/jac/dkag094 52 Comment on: ‘Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp’ 对“除塞拉蒂亚属（Serratia spp）外肠杆菌目所致心内膜炎的流行病学和治疗”的评论 Gianpiero Tebano and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag098, https://doi.org/10.1093/jac/dkag098 53 ‘Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–2021-right-to-reply’ “比较肺炎球菌疫苗的血清型覆盖率——PCV21（V116，一种新型21价结合肺炎球菌疫苗）与加拿大成人患者中导致侵袭性肺炎球菌疾病的其8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学：SAVE研究，2018 - 2021年——回应” John J Schellenberg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag126, https://doi.org/10.1093/jac/dkag126 54 Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus 评论：奥罗芬明与伏立康唑对烟曲霉的体外拮抗作用 Corinne Pinder and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag119, https://doi.org/10.1093/jac/dkag119 55 Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.: right-to-reply 除塞氏杆菌属外肠杆菌科细菌所致心内膜炎的流行病学和治疗：回应 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag121, https://doi.org/10.1093/jac/dkag121 Journal of Antimicrobial Chemotherapy Volume 81, Issue 5抗菌化疗杂志81卷 5期 https://academic.oup.com/jac/issue 50TH ANNIVERSARY COLLECTION（50周年纪念合集） REVIEW（综述） 1 A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage 针对动基体病的高质量先导化合物及药物开发候选物的战略发现路线图。第一部分：背景介绍 Sarah Hendrickx and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag109, https://doi.org/10.1093/jac/dkag109 REVIEW（综述） 2 Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury 多粘菌素相关急性肾损伤的病理生理学、危险因素及临床治疗 Simiao Zhao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag132, https://doi.org/10.1093/jac/dkag132 SYSTEMATIC REVIEW（系统综述） 3 Definitions and rates of treatment failure in females with uncomplicated urinary tract infection: a systematic literature review 女性单纯性尿路感染治疗失败的定义及发生率：一项系统文献综述 Meghan E Luck and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag112, https://doi.org/10.1093/jac/dkag112 4 Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review 在针对深部感染的β-内酰胺类抗生素优化给药方案中治疗药物监测以及药代动力学/药效学的作用：一项系统综述 Cassandra Vale and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag142, https://doi.org/10.1093/jac/dkag142 ORIGINAL RESEARCH（论著） 5 Optimizing cloxacillin prophylaxis in hip and knee arthroplasty based on population pharmacokinetics of unbound plasma concentrations 基于游离血浆浓度群体药代动力学优化髋关节和膝关节置换术中的氯唑西林预防用药方案 Gustaf Beijer and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag116, https://doi.org/10.1093/jac/dkag116 6 The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat 大鼠静脉注射[14C]奥洛罗芬后的组织分布及药代动力学研究 Derek Law and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag120, https://doi.org/10.1093/jac/dkag120 7 Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia 世界卫生组织三轮车项目（Tricycle）协同的弗莱明基金南亚和东南亚地区外部质量评估（EQASIA EQA）计划在检测南亚和东南亚地区产超广谱β-内酰胺酶（ESBL）、AmpC酶和碳青霉烯酶的大肠埃希菌方面的见解 Hiba Al-Mir and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag129, https://doi.org/10.1093/jac/dkag129 8 The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV HIV感染者肌内注射长效卡博特韦和利匹韦林后的血浆及细胞内暴露情况 Micol Ferrara and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag113, https://doi.org/10.1093/jac/dkag113 9 In vitro synergistic activity of minocycline and biapenem against cefiderocol-resistant New Delhi metallo-β-lactamase-producing Enterobacterales 米诺环素与比阿培南在体外对产新德里金属β-内酰胺酶且对头孢地尔耐药的肠杆菌科细菌的协同作用 Takashi Okanda and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag128, https://doi.org/10.1093/jac/dkag128 10 Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort 产超广谱β-内酰胺酶大肠埃希菌菌血症的死亡风险：基于PROBAC队列的综合分析 Paula Olivares-Navarro and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag130, https://doi.org/10.1093/jac/dkag130 11 Molecular mechanism of envZ regulating β-lactam antibiotic resistance and virulence in Escherichia coli EnvZ调控大肠埃希菌β-内酰胺类抗生素耐药性及毒力的分子机制 Kun Yang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag104, https://doi.org/10.1093/jac/dkag104 12 In vitro activity of amoxicillin combined with oral cephalosporins against endocarditis-associated E. faecalis clinical isolates 阿莫西林联合口服头孢菌素针对心内膜炎相关粪肠球菌临床分离株的体外活性 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag127, https://doi.org/10.1093/jac/dkag127 13 Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis 全基因组关联研究构建预测模型并揭示大环内酯类耐药百日咳鲍特菌的新耐药特征 Jialiang Chen and Guowei Liang Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag131, https://doi.org/10.1093/jac/dkag131 14 Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity 减量持续静脉输注头孢吡肟方案的实际应用验证：药效学目标达成情况、疗效及神经毒性 Kieffer Korvin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag138, https://doi.org/10.1093/jac/dkag138 15 Cross-species and cross-border spread of aph(3′)-ia-mediated neomycin resistance in Escherichia coli from animals: a genomic perspective 从基因组角度研究动物源大肠杆菌中aph(3′)-ia介导的新霉素耐药性的跨物种和跨国传播 Mattia Pirolo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag143, https://doi.org/10.1093/jac/dkag143 16 Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance 美国烟曲霉临床分离株集合中cyp51A变异体的流行情况及其对三唑类抗真菌药物耐药性作用的比较分析 Luisa Fernanda Gómez Londoño and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag124, https://doi.org/10.1093/jac/dkag124 17 In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance 达托霉素联合头孢洛林对高水平氨基糖苷类耐药及非耐药粪肠球菌所致实验性心内膜炎的体内外疗效研究 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag136, https://doi.org/10.1093/jac/dkag136 18 Pharmacokinetics of a three-dose regimen of intramuscular benzathine penicillin G in pregnant women with syphilis 三剂苄星青霉素G肌内注射方案在妊娠期梅毒患者中的药代动力学研究 Eshetie Melese Birru and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag145, https://doi.org/10.1093/jac/dkag145 19 Cefiderocol resistance mediated by mutation of the miniconductance mechanosensitive channel MscM in Klebsiella oxytoca 由产气克雷伯菌中微小电导机械敏感通道MscM发生突变所介导的头孢地尔耐药性 Pia Turowski and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag147, https://doi.org/10.1093/jac/dkag147 20 The veterinary clinic backyard lawn used for relief walks of hospitalized dogs is a hotspot for OXA-type carbapenemases in multiple Enterobacterales 兽医诊所后院供住院犬只散步的草坪是多种肠杆菌科细菌中OXA型碳青霉烯酶的传播热点区域 Yvonne Spahr and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag144, https://doi.org/10.1093/jac/dkag144 21 Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective 头孢唑林在减肥手术患者中的药代动力学：术前视角 Alexandra Porlier and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag150, https://doi.org/10.1093/jac/dkag150 RESEARCH LETTERS（研究快讯） 22 Plasmid-encoded FRI-10 carbapenemase harboured by non-Enterobacter species isolated from a wastewater sample in Tokyo, Japan 从日本东京废水样本中分离出的非肠杆菌科物种携带质粒编码的FRI-10碳青霉烯酶 Kou Murakami and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag133, https://doi.org/10.1093/jac/dkag133 23 Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants 头孢吡肟/恩美唑巴坦与美罗培南、哌拉西林、哌拉西林/他唑巴坦、西他沙星和磷霉素针对携带blaKPC等位基因变体的肺炎克雷伯菌的协同作用 Alice Crema and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag141, https://doi.org/10.1093/jac/dkag141 24 MRSA and carbapenem-resistant Acinetobacter baumannii on the fall: successful infection prevention and control in Chilean ICUs 耐甲氧西林金黄色葡萄球菌和耐碳青霉烯类鲍曼不动杆菌数量下降：智利重症监护病房感染预防与控制的成功案例 Patricio Ross and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag146, https://doi.org/10.1093/jac/dkag146 LETTER TO THE EDITOR（致编辑的信） 25 Comment on: Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic–pharmacodynamic modelling in adults and infants 评论：基于模型的评估VRC07-523LS在婴儿中的给药剂量——基于成人和婴儿群体药代动力学-药效学模型 Wanhua Qiu Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag139, https://doi.org/10.1093/jac/dkag139 26 Comment on: Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21 评论：比较含21种血清型的肺炎球菌疫苗PCV21（V116）（一种新型21价结合肺炎球菌疫苗）的血清型覆盖范围，以及2018 - 2021年SAVE研究中导致加拿大成年患者侵袭性肺炎球菌疾病的8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学情况 Gokul Raj Pullagura and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag125, https://doi.org/10.1093/jac/dkag125 27 Comment on: Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 评论：肉鸡源和人临床来源肠球菌分离株中NarAB的不同种群结构和基因组背景 Alex Wong Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag134, https://doi.org/10.1093/jac/dkag134 28 Distinct population structure and genomic context of narAB between broiler and human clinical Enterococcus isolates—authors’ response 肉鸡源和人临床来源肠球菌分离株中narAB的不同种群结构和基因组背景——作者回复 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag135, https://doi.org/10.1093/jac/dkag135 Journal of Antimicrobial Chemotherapy Volume 81, Issue 6抗菌化疗杂志81卷 6期 https://academic.oup.com/jac/issue 50TH ANNIVERSARY COLLECTION（50周年纪念合集） REVIEW（综述） 1 A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate 针对动基体疾病高质量先导化合物和药物开发候选物的战略发现路线图。第三部分：从先导化合物到药物开发候选物 Sarah Hendrickx and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag111, https://doi.org/10.1093/jac/dkag111 ORIGINAL RESEARCH（原创研究） 2 Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children 危重患儿中替加环素（Tigecycline）的群体药代动力学及目标达成概率研究 Wenjuan Hu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag156, https://doi.org/10.1093/jac/dkag156 3 Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica 假单胞菌属亚洲种（Pseudomonas asiatica）中金属β-内酰胺酶HMB-3的表型和基因型特征 Jacqueline Findlay and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag148, https://doi.org/10.1093/jac/dkag148 4 Early adequate linezolid concentrations and clinical outcomes in confirmed Gram-positive infections: the role of therapeutic drug monitoring 确诊的革兰氏阳性菌感染中早期达到适宜利奈唑胺浓度与临床预后的关系：治疗药物监测的作用 Daniel Fresán and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag137, https://doi.org/10.1093/jac/dkag137 5 Monte Carlo simulations identify suboptimal PK/PD target attainment with standard maribavir dosing 蒙特卡洛模拟表明标准剂量马立巴韦的药动学/药效学靶标达成情况欠佳 Yeleen Fromage and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag153, https://doi.org/10.1093/jac/dkag153 6 Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy 探究妊娠期间影响比克替拉韦暴露的药代动力学机制 L van der Wekken-Pas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag159, https://doi.org/10.1093/jac/dkag159 7 Artificial intelligence for analysing antibiotic use: an exploratory study in a tertiary care paediatric hospital in Italy 人工智能用于分析抗生素使用情况：意大利一家三级儿科医院的探索性研究 Elio Castagnola and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag162, https://doi.org/10.1093/jac/dkag162 8 Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance 氨曲南-阿维巴坦对产KPC变异体且对头孢他啶-阿维巴坦耐药的肺炎克雷伯菌的抗菌活性 Jingchun Kong and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag152, https://doi.org/10.1093/jac/dkag152 9 Highly transformable Haemophilus influenzae as a potential amplifier of quinolone resistance dissemination 高转化型流感嗜血杆菌作为喹诺酮耐药性传播的潜在放大器 Takeaki Wajima and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag160, https://doi.org/10.1093/jac/dkag160 10 Comparative nephrotoxicity of polymyxin B versus colistin: evidence from ensemble learning and propensity score matching 多黏菌素B与黏菌素的肾毒性比较：来自集成学习和倾向评分匹配的证据 Murat Özdede and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag044, https://doi.org/10.1093/jac/dkag044 11 Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections 模拟医院获得性单菌革兰氏阴性菌血流感染早期与晚期开始恰当抗生素治疗的对照试验 Abdullah T Aslan and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag161, https://doi.org/10.1093/jac/dkag161 12 Flufenamic acid resensitizes MRSA to gentamicin through synergistic ion modulation 氟苯尼考通过协同离子调节使MRSA对庆大霉素重新敏感 Xiaomin Ren and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag154, https://doi.org/10.1093/jac/dkag154 13 Description of OXA-244 carbapenemase-producing Escherichia coli in farm animals in The Netherlands, 2024 2024年荷兰农场动物中OXA-244碳青霉烯酶产大肠杆菌的描述 K T Veldman and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag155, https://doi.org/10.1093/jac/dkag155 14 Clinical outcomes of beta-bactam monotherapy versus beta-lactam plus azithromycin in hospitalized patients with community-acquired pneumoniae β-内酰胺类单药治疗与β-内酰胺类联合阿奇霉素治疗社区获得性肺炎住院患者的临床预后比较 Ilona Zhygalova Zhygalova and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag158, https://doi.org/10.1093/jac/dkag158 15 ‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort "不遗余力"：ODOACRE队列中多替拉韦+拉米夫定（DTG+3TC）作为转换方案长达10年的有效性、耐受性及代谢安全性结果 Arturo Ciccullo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag172, https://doi.org/10.1093/jac/dkag172 16 Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture 新型侧向流免疫层析检测试剂Certest ResisCheck® Carbapenemases用于革兰氏阴性菌培养物中碳青霉烯酶快速检测与鉴别的评估 Laura Monge-Olivares and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag149, https://doi.org/10.1093/jac/dkag149 17 Temocillin efficacy and emergence of resistance in Enterobacter cloacae Complex in a murine peritonitis model 替莫西林对产气肠杆菌复合群的疗效及耐药性演变：小鼠腹膜炎模型研究 N Alanbari and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag151, https://doi.org/10.1093/jac/dkag151 18 Temporal association between aerosolized colistin use and colistin resistance in the ICU: a time-series analysis ICU中雾化粘菌素使用与粘菌素耐药之间的时间关联：一项时间序列分析 Weechang Kang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag169, https://doi.org/10.1093/jac/dkag169 19 Can antimicrobial stewardship programmes be implemented during an armed conflict? A retrospective interventional cohort study 武装冲突期间能否实施抗菌药物管理计划？一项回顾性干预性队列研究 Hailie D Uren and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag115, https://doi.org/10.1093/jac/dkag115 20 Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy 伏立康唑治疗与CYP2C19表型：识别可能需要替代抗真菌治疗的患者 Eman Wehbe and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag168, https://doi.org/10.1093/jac/dkag168 21 Impact of cardiopulmonary bypass on cefuroxime plasma and interstitial tissue concentrations in patients undergoing cardiac bypass surgery—a prospective controlled clinical trial 体外循环对心脏旁路手术患者头孢呋辛血浆及组织间质浓度的影响——一项前瞻性对照临床试验 Stefanie Nothofer and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag171, https://doi.org/10.1093/jac/dkag171 22 Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia 对碳青霉烯耐药鲍曼不动杆菌肺炎危重患者中埃拉环素的药代动力学分析及给药方案优化 Luqi Lou and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag178, https://doi.org/10.1093/jac/dkag178 23 Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex 氨曲南/阿维巴坦与氨曲南联合头孢他啶/阿维巴坦对抗嗜麦芽窄食单胞菌复合群的耐久性和机制性能比较 Ashlan J Kunz Coyne and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag177, https://doi.org/10.1093/jac/dkag177 24 High-dose daptomycin for the treatment of invasive infections due to Enterococcus faecalis isolates with intermediate susceptibility 高剂量达托霉素治疗粪肠球菌中介敏感株所致侵袭性感染的疗效 Sidney Drake and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag179, https://doi.org/10.1093/jac/dkag179 25 Updated mapping of Plasmodium falciparum kelch13 gene polymorphisms in Madagascar, 2024 2024年马达加斯加恶性疟原虫kelch13基因多态性的最新图谱更新 Camille Roesch and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag181, https://doi.org/10.1093/jac/dkag181 26 Efficacy of ceftazidime/avibactam against 10 clinical isolates of Pseudomonas aeruginosa in icodextrin-based peritoneal dialysis solution and patient-derived dialysate 头孢他啶/阿维巴坦针对icodextrin基腹膜透析液及患者来源透析液中10株铜绿假单胞菌临床分离株的抗菌活性 Stephanie Supparitsch and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag185, https://doi.org/10.1093/jac/dkag185 27 Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes 头孢德罗对PERSEUS研究中多重耐药分离株的抗菌活性：头孢德罗最低抑菌浓度与临床预后之间的关系 Rafael Cantón and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag164, https://doi.org/10.1093/jac/dkag164 28 Class 1 DISARM system in restriction of conjugative carbapenemase-encoding plasmids in Klebsiella pneumoniae sequence type 23 1类DISARM系统对肺炎克雷伯菌ST23中接合型碳青霉烯酶编码质粒的限制作用 Qingqing Du and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag167, https://doi.org/10.1093/jac/dkag167 29 Acute kidney injury following amikacin therapy: a retrospective cohort study 阿米卡星治疗后急性肾损伤：一项回顾性队列研究 Iris Zohar and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag188, https://doi.org/10.1093/jac/dkag188 30 Performance of EUCAST disc diffusion and supplementary methods to detect reduced susceptibility to linezolid in enterococci— the NordicAST LRE-study EUCAST纸片扩散法及补充方法检测肠球菌利奈唑胺低敏感性的表现——NordicAST LRE研究 Bjørg Christina Haldorsen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag174, https://doi.org/10.1093/jac/dkag174 31 In vitro exposure to non-antipseudomonal antibiotics (NAPA) induces Pseudomonas aeruginosa resistance to antipseudomonal antibiotics (APA) 体外暴露于非抗假单胞菌抗生素（NAPA）可诱导铜绿假单胞菌对抗假单胞菌抗生素（APA）产生耐药性 David Lasry and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag182, https://doi.org/10.1093/jac/dkag182 32 Sub-inhibitory polyether ionophores enhance resistance plasmid transfer and transiently perturb the broiler gut resistome 亚抑制浓度的聚醚离子载体可促进耐药质粒转移并暂时扰乱肉鸡肠道耐药组 Jingyue Yang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag190, https://doi.org/10.1093/jac/dkag190 33 Influence of a putative TonB-dependent receptor on cefiderocol susceptibility in clinical Enterobacter hormaechei isolates 推测的TonB依赖性受体对临床肠杆菌hormaechei分离株中头孢地尔敏感性的影响 Pia Turowski and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag193, https://doi.org/10.1093/jac/dkag193 RESEARCH LETTERS（研究快报） 34 Early bictegravir failure and emergence of R263K-mediated class-wide HIV integrase inhibitors resistance linked to over-the-counter supplement use 比克替拉韦早期治疗失败与R263K介导的与非处方补充剂使用相关的全类HIV整合酶抑制剂耐药的出现 Elisa Minacori and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag157, https://doi.org/10.1093/jac/dkag157 35 Environmental benefits of switching from intravenous to oral administration of ciprofloxacin 环丙沙星从静脉给药转换为口服给药的环境效益 Nicolas De Jaegher and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag163, https://doi.org/10.1093/jac/dkag163 36 Macrolide resistance via 23S rRNA gene mutation in Corynebacterium ulcerans 白喉棒状杆菌通过23S rRNA基因突变介导的大环内酯类耐药 Chiara Crestani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag166, https://doi.org/10.1093/jac/dkag166 37 Prosthesis-associated Burkholderia cepacia complex infection managed with sequential directed therapy including ceftolozane/tazobactam 采用包括头孢妥仑/他唑巴坦在内的序贯导向疗法治疗假体相关洋葱伯克霍尔德菌复合感染 Elia Asensi-Díaz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag165, https://doi.org/10.1093/jac/dkag165 38 Drug interactions and kidney safety of bictegravir/emtricitabine/tenofovir alafenamide in kidney transplant recipients with HIV: an interventional pilot study 比克替拉韦/恩曲他滨/丙酚替诺福韦在合并HIV的肾移植受者中的药物相互作用及肾脏安全性：一项干预性 pilot 研究 Thomas Stehlé and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag176, https://doi.org/10.1093/jac/dkag176 39 Harmonizing antimicrobial susceptibility testing: a comparison of CLSI and EUCAST categorizations 抗菌药物敏感性试验的协调：CLSI与EUCAST分类法的比较 Eric Farfour and Marie Lavollay Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag081, https://doi.org/10.1093/jac/dkag081 LETTER TO THE EDITOR（致编辑的信） 40 Comment on: Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study 对"负荷剂量β-内酰胺类治疗对非ICU患者产KPC肺炎克雷伯菌血流感染结局的影响：一项现实研究"的评论 Xuefeng Yu Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag173, https://doi.org/10.1093/jac/dkag173 41 Comment on: ‘Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure’ 评论："HIV-1整合酶天然多态性K156N与3′PPT突变在多替拉韦单药治疗失败中的协同作用" Muhammad Ifham Hanif and Mentari Maratus Sholihah Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag175, https://doi.org/10.1093/jac/dkag175 Journal of Antimicrobial Chemotherapy Volume 81, Issue Supplement_1抗菌化疗杂志81卷增刊1期 https://academic.oup.com/jac/issue/81/Supplement_1?login=false SUPPLEMENT（增刊） Breaking Evidence and Insights into Effective Utilization and Implementation of Procalcitonin 降钙素原有效利用与实施的突破性证据与见解 VIRTUAL ROUNDTABLE（线上圆桌论坛） 1 Procalcitonin in the management of lower respiratory tract infection and sepsis 降钙素原在下呼吸道感染和脓毒症治疗中的应用 Ramy H Elshaboury and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue Supplement_1, June 2026, Pages i1–i5, https://doi.org/10.1093/jac/dkaf298 VIEWPOINT（观点） 2 Beyond the algorithm: reframing biomarker-guided antibiotic stewardship with behavioural insights 超越算法：以行为学见解重构生物标志物导向的抗菌药物管理 Patrycja Sleboda and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue Supplement_1, June 2026, Pages i6–i8, https://doi.org/10.1093/jac/dkag140 CORRECTION（更正） 3 Correction to: Procalcitonin in the management of lower respiratory tract infection and sepsis 更正：降钙素原在下呼吸道感染和脓毒症治疗中的应用 Journal of Antimicrobial Chemotherapy, Volume 81, Issue Supplement_1, June 2026, Page i9, https://doi.org/10.1093/jac/dkag170

2026-06-20

·摸鱼心灵之声

罕见病本周十件大事：基因疗法BLA破局、抗真菌孤儿药、胰岛移植ODD、医保双目录收官

FDA突然宣布了一个让整个行业震惊的决定：uniQure的亨廷顿病基因疗法AMT-130，不需要做那场备受争议的假手术对照III期试验了！FDA同意直接用现有的I/II期数据走加速批准通道。消息一出，uniQure股价瞬间暴涨60%——这是对无数等待了太久的HD患者家庭的最好回应。同一天，Lexeo的Friedreich共济失调基因疗法LX2006登上了JAMA Cardiology，17例患者零严重不良事件，心脏指标改善最高达33%。 F2G和盐野义的口服抗真菌新药Olorofim在III期中大获成功。从监管突破到顶刊发表，从基因疗法到抗感染孤儿药——今天的10条新闻，每一条都承载着某个群体的殷切期盼。罕见病从来不是"小众"问题。全球7亿+罕见病患者，每个数字背后都是一个鲜活的生命、一个焦虑的家庭、一段不屈的抗争故事。让我们看看今天这个世界又为他们带来了什么新的希望。罕见病最新进展 1. uniQure AMT-130亨廷顿病基因疗法迎FDA历史性逆转——同意以3年期数据作为BLA加速批准依据，股价飙升60% 6月17日，荷兰基因治疗公司uniQure N.V.（NASDAQ: QURE）发布重磅消息：美国FDA已明确同意接受其亨廷顿病（Huntington's Disease, HD）基因疗法AMT-130的I/II期临床研究3年分析数据，作为提交生物制品许可申请（BLA）加速批准的主要依据。公司计划于2026年第三季度正式递交BLA。【监管大逆转的来龙去脉】这一决定标志着FDA对AMT-130的监管态度发生了根本性转变。回顾今年5月初，FDA曾要求uniQure进行一项假手术对照（sham-controlled）III期临床试验——这在业界引发了巨大争议，因为对神经退行性疾病患者进行假手术脑部操作存在严重的伦理和可行性问题。如今，FDA不仅收回了"硬性要求假手术对照"的立场，还主动提出： • 同意将AMT-130的3年临床数据与Enroll-HD自然病史外部对照组进行比较 • 确认加速批准（Accelerated Approval）路径可行 • 预计30天内发布最终会议纪要受此利好消息刺激，uniQure股价当日开盘大涨60%，创下公司历史单日最大涨幅记录。【关于AMT-130与亨廷顿病】 AMT-是一款基于腺相关病毒（AAV）载体的基因沉默疗法，通过microRNA（miRNA）机制靶向降低突变 huntingtin 蛋白（mHTT）的表达。该药物通过MRI引导下的颅内给药，仅需单次注射。 • I/II期研究入组26名早期显性HD患者（16例治疗 + 10例假手术） • 欧洲开放标签研究额外纳入13名患者 • 已获得FDA三项重磅认定：RMAT + 突破性疗法 + 快速通道亨廷顿病是一种常染色体显性遗传的致命性神经退行性疾病，由HTT基因CAG重复扩增引起。患者通常在中年起病，表现为不自主运动（舞蹈症）、认知衰退和精神症状，病程约15-20年，目前无任何疾病修饰治疗手段可用。全球患病人数约5-10万人。【行业影响】这是FDA首次同意基于单一区域I/II期数据+外部对照组比较的方式批准神经退行性疾病的基因疗法，为同类产品的开发树立了全新的监管先例。对于苦苦等待"第一款HD有效药物"的患者家庭而言，这一天等了太久了——如今曙光终于真正照进了现实。 �� 来源：BioWorld 2026-06-18 / Market Chameleon / BioSpace新闻稿 / GlobeNewswire / rare disease.cn / finviz 2. Lexeo LX2006 Friedreich共济失调基因疗法I/II期数据荣登JAMA Cardiology——心脏生物标志物改善28-33%，零严重不良事件 6月17日，美国Lexeo Therapeutics（NASDAQ: LXEO）宣布其针对Friedreich共济失调（Friedreich's Ataxia, FA）心肌病的基因疗法LX2006的I/II期临床试验数据正式发表于心血管领域顶级期刊《JAMA Cardiology》。这项研究整合了Weill Cornell Medicine学术研究和Lexeo主导的SUNRISE-FA临床试验共计17例患者数据，是该疾病领域迄今最全面的基因治疗人体数据集之一。【核心疗效数据】 LX2006是一款基于AAVRh.10载体的静脉输注（IV）基因疗法，旨在递送功能性frataxin（FXN）基因至心脏组织，修复FA患者因FXN蛋白缺陷导致的心肌病。关键发现包括： �� 心脏结构指标（最核心终点）： • 左室质量指数（LVMI）：中高剂量组6个月改善28%，12个月改善33% • 大多数参与者显示LVMI持续改善或稳定 • 部分患者在治疗后三年仍维持改善——证明持久的疾病修饰效果 �� 生物标志物突破： • 所有8例SUNRISE-FA心脏活检参与者在3个月时均实现frataxin蛋白表达增加 • 这是**首次在疾病相关心脏组织中获得有意义的FXN恢复证据** • 高敏肌钙蛋白I：大多数患者改善或稳定 • 侧壁厚度：改善或稳定 �� 神经功能信号： • 改良Friedreich Ataxia评分量表（mFARS）：LX2006与神经功能稳定化相关 • 提示心脏基因治疗的获益可能延伸至神经系统【安全性概况：极其出色】 • 17例受试者总体耐受性良好 • ≥3级严重不良事件（SAE）：**0例** • 具有临床意义的补体激活：无 • 唯一值得关注的事件：1例患者出现2级无症状心肌炎（Grade 2，可能相关） • 肝功能检测异常：极少且一过性【后续开发计划】 • SUNRISE-FA 2关键性注册试验方案已确定，预计2026年Q2启动（即6月底前） • 顶线数据预计2027年下半年公布 • FDA加速审批通道已确认适用【关于Friedreich共济失调】 FA是最常见的遗传性共济失调，由FXN基因GAA扩增导致frataxin蛋白缺乏引起。患者通常在儿童期或青春期起病，表现为进行性运动协调障碍、心肌病、糖尿病和脊柱侧弯。心脏病是FA患者的首要死因——约60%的患者死于心力衰竭相关并发症。目前无任何获批的心脏特异性治疗。正如论文通讯作者、Weill Cornell医学中心的Ronald G. Crystal教授所言："Friedreich共济失调心肌病仍是一种进行性且危及生命的疾病，尚无获批的心脏特异性治疗方法。这些发现强化了基因疗法解决疾病根源的潜力。" �� 来源：JAMA Cardiology 2026-06-17 / Lexeo IR官网 / BioPharmaWatch / StockTitan / Manila Times / GlobeNewswire 3. F2G×盐野义Olorofim III期OASIS试验达非劣效主要终点——侵袭性曲霉病患者有望迎来40年来首个全新机制口服抗真菌药 6月18日，英国生物技术公司F2G Limited与日本盐野义制药（Shionogi, TYO: 4507）联合宣布，双方合作开发的口服抗真菌新药Olorofim（代号OAT-203/F901318）在全球多中心III期临床试验OASIS（NCT05101187）中达到主要终点，展现出与标准治疗方案的非劣效性。【OASIS III期试验关键结果】 OASIS是一项随机、开放标签、全球多中心III期临床研究，评估Olorofim对比两性霉素B脂质体（AmBisome®）序贯标准治疗在侵袭性曲霉病（Invasive Aspergillosis, IA）患者中的疗效和安全性： �� 主要终点（全因死亡率Day 42）： • Olorofim组：23.8% • AmBisome序贯SOC组：24.3% • 结果：达到预设的非劣效性界值 ✅ �� 试验设计亮点： • 全球多中心入组 • 侵袭性曲霉病是免疫受损患者（血液肿瘤移植后、长期免疫抑制等）面临的最致命真菌感染之一 • 传统治疗方案需要静脉给药，而Olorofim是口服制剂——这对患者生活质量的改善意义重大【关于Olorofim：全新机制的orotomide类抗真菌药】 Olorofim属于全新化学类别"orotomide"，通过抑制真菌二氢乳清酸脱氢酶（DHODH）发挥作用——这是一个与传统唑类和多烯类完全不同的作用靶点。这意味着： ✅ 对多种耐药真菌株保持活性 ✅ 口服生物利用度高 ✅ 可覆盖曲霉菌、毛霉菌等多种难治性真菌 ✅ 40年来首个全新机制系统性抗真菌药【后续计划与行业意义】两家公司表示正基于此积极的数据准备向FDA和其他监管机构提交上市申请。此前F2G已完成1亿美元融资专门用于Olorofim的重新申报工作（该药去年曾被FDA拒绝过一次）。盐野义作为合作伙伴将负责日本的商业化。对于每年数万名因血液恶性肿瘤或器官移植而面临侵袭性曲霉病死亡风险的患者而言，一款高效、口服、新型机制的抗真菌药意味着生存机会的实质性提升。 �� 来源：The Pharma Letter 2026-06-18 / TMCnet / Manila Times GlobeNewswire / VBData / PharmaForum 4. Sernova自体胰岛移植获FDA孤儿药认定——全胰腺切除术后糖尿病预防迎来细胞治疗新路径 6月17日，加拿大再生医学公司Sernova Biotherapeutics（TSX: SVA.TO）宣布，美国FDA已授予其自体胰岛移植（Autologous Islet Transplantation, AIT）疗法用于预防全胰腺切除术后糖尿病的孤儿药资格认定（Orphan Drug Designation, ODD）。【什么是全胰腺切除术后糖尿病？】全胰腺切除术（Total Pancreatectomy）是某些严重胰腺疾病的最终治疗手段，包括： • 无法手术切除的慢性胰腺炎伴剧烈疼痛 • 胰腺导管内乳头状黏液瘤（IPMN）伴高级别异型增生 • 早期胰腺癌（特定情况下）全胰切除后，患者因失去全部内源性胰岛素分泌能力，必然发生胰腺切除术后糖尿病（Post-pancreatectomy Diabetes），需要终身外源性胰岛素替代治疗。这种类型的糖尿病管理极具挑战性： • 完全丧失内源性血糖调节机制 • 严重低血糖和高血糖交替发作 • 生活质量显著下降 • 属于极罕见适应症——年发病率远低于20万/年阈值【Sernova的细胞治疗解决方案】 Sernova的自体胰岛移植策略利用患者自身的胰岛细胞，结合公司的专有细胞袋（Cell Pouch™）平台技术： • 从患者自身胰腺中分离胰岛细胞 • 植入Cell Pouch™（一种可植入的细胞输送装置） • 移植回患者体内前臂皮下空间 • 细胞在装置内定植并重建内源性胰岛素分泌功能 • 无需免疫抑制（因为是自身细胞） FDA孤儿药认定将为该项目带来以下政策支持： • 研发税收抵免 • 用户费减免 • FDA批准后7年美国市场独占期 • 优先审评券（如同时获得RPDD）资格【战略意义】这是再生医学在罕见代谢疾病领域的又一重要探索。虽然适应症患者群体较小，但"自体细胞移植+免免疫抑制"的技术平台具有向更广泛的1型糖尿病等领域扩展的潜力。 �� 来源：RTTNews 2026-06-17 / Sernova官方新闻稿 / Manila Times / Trial MedPath / Finanzen.at 5. 辉瑞HYMPAVZI®扩大适应症获FDA批准——覆盖血友病A/B抑制剂患者及6-11岁儿童 6月8日，辉瑞公司（Pfizer, NYSE: PFE）宣布美国FDA已批准扩大HYMPAVZI®（marstacimab-hncq）的适用范围，新增两大重要人群：【扩展适应症详情】 1️⃣ **伴有凝血因子VIII抑制物的血友病A成人及≥6岁儿科患者** 2️⃣ **伴有凝血因子IX抑制物的血友病B成人及≥6岁儿科患者** 此前，HYMPAVZI仅获批用于12岁及以上且不伴有抑制物的血友病A/B患者的常规预防治疗。【为什么这次扩展如此重要？】 �� 血友病治疗中的"最大挑战"——抑制物：约20-30%的血友病A患者和1-5%的血友病B患者在反复接受因子替代治疗后会产生中和抗体（称为"抑制物"），使标准因子替代疗法失效。这些患者曾经被称为"最难治的血友病群体"。 �� 儿童患者终于有了选择：此次扩展特别重要的一点是：HYMPAVZI成为**首款适用于6至11岁血友病B儿科患者的皮下给药非凝血因子预防疗法**。在此之前，这一年龄段的小患者几乎没有合适的预防性治疗方案。 �� 用法优势： • 每周一次皮下注射（无需静脉输注） • 非因子替代机制（靶向TFPI通路），对有/无抑制物患者均有效 • 居家自行给药，大幅提升便利性和生活质量【关于血友病背景】血友病A和B均为X连锁隐性遗传出血性疾病，分别由凝血因子VIII和IX缺乏引起。全球约有40万血友病患者，其中约75%未得到充分诊断或治疗。在中国，随着诊疗水平提升和医疗保障完善，越来越多的血友病患儿正在从"致残致死"走向"正常生活"。HYMPAVZI这类创新疗法的可及性提升将进一步改变这个群体的命运轨迹。 �� 来源：辉瑞官方新闻稿2026-06-08 / 搜狐医药 / Hemophilia Federation / HEMOB.org / FDA.gov / VBData 6. Roche Lunsumio®皮下注射制剂+Polivy联合疗法sBLA获FDA正式受理——DLBCL复发难治患者迎来免静脉化疗新选择 6月18日，罗氏制药（Roche, SIX: RO）宣布美国FDA已正式受理其补充生物制品许可申请（sBLA），寻求批准Lunsumio®（mosunetuzumab）皮下注射制剂（VELO™剂型）联合Polivy®（polatuzumab vedotin）用于治疗复发或难治性弥漫大B细胞淋巴瘤（r/r DLBCL）。【关于这款联合疗法】 �� Lunsumio（Mosunetuzumab）： • CD20×CD3双特异性T细胞衔接抗体（TCE） • 通过桥接T细胞和B细胞，引导免疫系统杀伤恶性B细胞 • 新开发的皮下注射（SC）制剂——VELO™技术平台 • 相比传统静脉输注，皮下注射仅需数分钟完成 ⚔️ Polivy（Polatuzumab vedotin）： • CD79b靶向抗体药物偶联物（ADC） • 与CD20×CD3双抗形成"双重打击"机制 • 已在全球多个国家获批用于DLBCL三线以上治疗【DLBCL：最常见的侵袭性淋巴瘤】弥漫大B细胞淋巴瘤是非霍奇金淋巴瘤中最常见的亚型，约占所有NHL病例的30-35%。虽然一线R-CHOP方案可使部分患者治愈，但仍有约40%的患者复发或难治。对于这部分患者而言，后续治疗选择有限，预后较差——CAR-T细胞疗法虽有效但费用高昂（国内约120万元/针），且需要复杂的医疗基础设施支持。 Lunsumio皮下制剂如果获批，将提供一个"门诊级"的治疗选项： • 无需住院静脉化疗 • 给药时间短（皮下 vs 数小时输液） • 制造和储存成本更低 • 可能显著降低治疗门槛【时间节点】 FDA正在审核该sBLA申请，审评周期通常为8-10个月。罗氏在血液瘤领域持续投入，Lunsumio皮下制剂代表了"让更多患者用得起创新疗法"的战略方向。 �� 来源：Roche官方媒体发布2026-06-18 / Roche.com / MFN.se / StockTitan / Ritzau / assets.roche.com 7. 第三届中国罕见病科研大会（HRSC 2026）即将于6月25-27日在上海隆重开幕由中国罕见病科研领域最重要的年度学术盛会——第三届中国罕见病科研大会（Hope for Rare Science Conference, HRSC 2026）将于2026年6月25日至27日在上海浦东三甲港国际会议中心盛大召开。【大会基本信息】 • �� 时间：2026年6月25日-27日（两天半） • �� 地点：中国·上海浦东三甲港国际会议中心 • �� 规模：超80位国内外讲者确认出席 • ��️ 主办方：瑞鸥公益基金会 • �� 联合主办：国家儿童医学中心复旦大学附属儿科医院、蔻德罕见病中心 • �� 专设论坛：22个专业分论坛/专场【大会亮点前瞻】 �� 科学前沿聚焦： • 基因编辑（CRISPR/碱基编辑/先导编辑）最新临床转化进展 • AAV载体工程化与递送技术创新 • RNA疗法（mRNA/circRNA/siRNA/反义寡核苷酸）平台突破 • 体内CAR-T与通用型CAR-T技术革命 • AI驱动的新药发现与罕见病靶点筛选 �� 临床诊疗实践： • 婴儿癫痫性脑病（包括WWOX相关癫痫性脑病等最新基因治疗案例） • 结节性硬化症（TSC）多学科诊疗 • 代谢性疾病酶替代治疗与基因治疗 • 罕见肿瘤精准诊疗 • 新生儿筛查与早期干预 �� 政策与生态建设： • 医保与商保"双目录"调整落地经验分享 • 中国罕见病定义与目录更新 • 患者组织赋能与多方协作模式 • 国际罕见病政策比较与借鉴【为什么这场大会值得关注？】 2026年是中国罕见病领域的"制度元年"——5月起施行的国务院第818号令建立了细胞与基因治疗的双轨制监管框架；医保商保双目录联动调整首次引入未上市I类创新药预申报机制。HRSC 2026恰逢其时地汇聚了科学家、临床医生、患者代表和政策制定者，有望成为推动中国罕见病生态从"跟跑"到"领跑"的关键枢纽事件。对于罕见病病友和家庭而言，这场大会上发布的每一项研究成果、每一个政策动向，都可能直接关系到未来的治疗希望和生活质量。 �� 来源：Hope4Rare瑞鸥公益基金会 / raredisease.cn / 腾讯新闻2026-04-15 / HRSC 2026注册通知 8. 医保商保"双目录"申报818份圆满收官——罕见药单独申报通道打开，9月评审结果备受期待 6月10日，2026年国家医保药品目录和商业健康保险创新药品目录调整申报系统正式关闭。据国家医保局随后公布的数据，本次调整共收到**818份申报**，其中涉及目录外药品570份（含509份单独申报医保目录、44份同步申报医保+商保双目录、17份单独申报商保目录），另有61份涉及商保目录申报。值得注意的是，本次首次引入了14款尚未上市的I类创新药的预申报机制，其中包含多款罕见病治疗药物。【"双目录"联动调整：2026年的重大制度创新】 2026年的医保目录调整有一个前所未有的特点——基本医保目录与商业健康保险创新药目录实现**同步申报、同步评审、联动调整**。这一改革的核心逻辑是： �� "医保保基本，商保保高端"： • 国家基本医保：聚焦临床必需、安全有效、价格合理的药品 • 商业健康险：覆盖创新药、高价药、罕见病药等医保未能充分覆盖的领域 • 双目录联动：避免重复评审，提高效率，为患者提供多层次保障 �� 罕见病药品的政策红利： • 罕见病独家药品可**单独申报**商保目录 • 未上市I类创新药可通过**预申报机制**提前进入对价流程 • 这意味着一款罕见病新药可能在获批上市之前就已经开始了支付端谈判【申报数据分析：818份背后的故事】 • 目录外申报570份 → 创新高 • 44份选择"双报"（医保+商保同步）→ 企业对商保渠道重视度空前 • 17份仅报商保 → "纯商保"策略开始出现 • 14款未上市I类药预申报 → 创新加速信号强烈【9月公布结果后的影响】根据工作方案，评审结果将于2026年9月前后公布。对于罕见病病友群体而言，以下几个时间节点值得密切关注： • 9月：初审结果公示（哪些罕见药进入谈判环节） • Q4：专家评审与价格谈判 • 年底前：新版目录公布执行【惠民保的桥梁作用】截至2026年初，全国已有超过19种罕见病药物被纳入各地惠民保（城市定制型商业医疗保险）保障范围。商保目录的建立有望进一步规范和创新这一渠道，使更多罕见病用药从"望尘莫及"变为"触手可及"。 �� 来源：腾讯新闻2026-06-11 / 新浪财经 / 国家医保局官网 / 新华社解读 / 政府网gov.cn /新京报搜狐 9. Morgan Stanley中国生物医药峰会今日在上海隆重举行——AI制药重塑罕见病研发范式成焦点议题 6月17-18日，摩根士丹利（Morgan Stanley）2026年中国生物医药峰会在上海盛大召开。这场汇聚了全球顶尖投资人、跨国药企高管和中国创新药企领袖的行业盛会，将"AI驱动的药物发现"列为核心议题之一。【Insilico Medicine：AI制药的旗帜性企业】峰会最受关注的演讲嘉宾之一是Insilico Medicine创始人兼CEO Alex Zhavoronkov博士。该公司是全球AI制药领域的领军企业，其核心技术平台PandaOmics（AI靶点发现）+ Chemistry42（AI分子生成）+ InClinico（AI临床试验预测）构成了完整的端到端AI药物研发管线。【AI如何改变罕见病药物研发？】罕见病药物研发的传统痛点： ❌ 患者群体小→难以招募足够临床试验受试者 ❌ 疾病机制不明→靶点发现困难 ❌ 研发成本高→投资回报率低 ❌ 数据分散→知识积累慢 AI带来的变革： ✅ 知识图谱+文献挖掘→快速锁定潜在靶点 ✅ 生成式AI分子设计→缩短先导化合物优化周期 ✅ 虚拟患者模型→优化临床试验设计 ✅ 多组学数据整合→揭示超罕见病的致病机制【中国AI制药的"元年效应"】 2026年被广泛认为是中国AI制药的"元年"： • 晶泰科技×溪砾科技合作的RTX-117成为国内首款获中美IND双批件的AI+RNA融合新药 • 百图生科、英矽智能、华深智药等多家AI制药公司进入临床阶段 • 跨国药企（礼来、阿斯利康、诺华等）加大在华AI研发布局 • 政策层面，《生物医学新技术条例》为AI辅助研发提供了法规框架【对罕见病群体的意义】 AI技术的成熟可能从根本上改变罕见病药物研发的经济学方程式——当靶点发现成本下降90%、先导化合物优化从3年缩短到6个月时，那些曾经因为"市场太小"而被放弃的超罕见病，重新变得具有可研发性。这对于全球3亿+罕见病患者来说，可能是最大的希望来源之一。 �� 来源：Eurekalert 2026-06 / BioEngineer / BrightSurf / Noah-News / Morgan Stanley官方议程 10. RedHill Opaganib获FDA罕见儿科疾病认定——神经母细胞瘤儿童患者迎来潜在PRV优先审评机遇 6月9日，以色列 specialty biopharma 公司RedHill Biopharma（NASDAQ: RDHL）宣布，美国FDA已授予其在研新药Opaganib（Yeliva®）用于治疗神经母细胞瘤（Neuroblastoma）的罕见儿科疾病认定（Rare Pediatric Disease Designation, RPDD）。【关于Opaganib】 Opaganib是一款口服选择性泛SK2（鞘氨醇激酶2）抑制剂，具有独特的"双管齐下"作用机制： • 抑制SK2→减少促存活信号（通过SK2/S1P通路） • 同时抑制DHODH→干扰嘧啶合成（类似Olorofim的作用靶点之一） • 这种双靶点机制赋予Opaganib广谱的抗肿瘤活性，尤其在实体瘤中展现潜力【关于神经母细胞瘤——儿童"癌症之王"】神经母细胞瘤（NB）是婴幼儿期最常见的颅外实体恶性肿瘤，起源于交感神经系统前体细胞： • 发病率：每百万儿童约10例（占所有儿童肿瘤的8-10%） • 高危人群：绝大多数（90%）确诊时年龄<5岁 • 高危NB预后极差：即使经过强化治疗，5年总生存率仅约40-50% • 复发/难治性NB：几乎无有效治疗手段 • 年发病：美国每年约700-800例新诊病例【RPDD认定的含金量】 FDA罕见儿科疾病认定虽然本身不提供审评加速，但其真正的价值在于——一旦该药物后续获得同一儿科适应症的上市批准，公司将有资格获得一张**优先审评券（Priority Review Voucher, PRV）**。 • PRV可在任意药物的NDA/BLA申请中使用，将审评周期从标准的10个月缩短至6个月 • PRV可自由转让，历史上售价高达1亿-3.5亿美元 • Opaganib目前已同时拥有孤儿药认定（ODD）+ 罕见儿科疾病认定（RPDD）【RedHill的研发管线格局】 Opaganib在RedHill的管线中占据核心地位，除神经母细胞瘤外，还在探索COVID-19、前列腺癌等适应症。此次RPDD认定进一步丰富了公司在罕见儿科肿瘤领域的产品布局。 �� 来源：PR Newswire 2026-06-09 / Morningstar / Market Chameleon / AI Journ / Trial MedPath 11. 深度观察：2026年中罕见病领域五大趋势——从「监管反转」到「支付创新」，一个加速奔跑的时代站在2026年年中的时间节点回望过去半年，罕见病领域正在经历一场前所未有的"加速度"变革。以下是五大值得关注的趋势性变化：趋势一：监管态度从"保守谨慎"转向"积极灵活" 以uniQure AMT-130为例——短短一个月内，FDA从"要求假手术III期"到"接受I/II期数据+外部对照加速批准"，这种转变释放出的信号非常明确：监管机构愿意为真正有潜力的罕见病创新疗法开辟绿色通道。同样，FDA基因组编辑先验知识指南草案、合理机制框架等政策的陆续出台，都在降低基因疗法的研发门槛和时间成本。趋势二："中国力量"从参会者变成引领者 EHA 2026上中国34项Oral入选（历史新高）、ASCO 2026上中国94项口头报告+12项LBA创纪录——这不再是简单的数字增长，而是质的飞跃。碱基编辑（正序生物CS-206）、体内CAR-T（传奇LB2501）、RNA编辑（LEAPER/DMD Cell论文登Cell）等原创性突破正在从中国的实验室走向世界舞台中央。趋势三：支付体系从"单一医保"走向"多层保障" 医保商保"双目录"联动调整、惠民保覆盖19种罕见药、预申报机制引入未上市I类药——这些制度创新的叠加效应正在逐步显现。罕见病用药"进医保难"的困局，正在被多层次支付体系的建设所逐步破解。趋势四：技术平台从"一病一药"走向"平台化覆盖" • Eloxx ELX-02的无义突变通读疗法理论上可覆盖数百种遗传病（CF-Alport-DMD-RP等） • AAV载体工程化（Dyno Capsid.AI/Apertua TfR1 CapX）使一个载体平台可适配多种中枢神经系统疾病 • mRNA-LNP体内CAR-T（虹信/圆因/嘉晨/石药）使同一个递送技术可用于不同靶点平台化研发模式的成熟，正在从根本上改变罕见病药物研发的经济学。趋势五：患者角色从"被动受试者"转向"主动参与者" 从SPG50患者主导的CGTxchange项目到Baby KJ案例催生的CIRM RAPID计划，患者组织不再仅仅是临床试验的"受试者来源"，而是成为了推动超罕见病研究的发起者和资助者。HRSC 2026大会也将患者声音纳入核心议程——这种转变或许比任何单一药物突破都更加深远。【给病友的话】如果你正在阅读这篇文章，你或你的家人可能正在与某种罕见病抗争。请相信：每一天，全球都有数千名科学家、医生、监管者和患者在为你我而努力。2026年的这股"加速度"不会停止——它只会越来越快，直到每一种罕见病都有药可医。 �� 来源：综合分析 / BioWorld / FierceBiotech / raredisease.cn / Endpoints News / 证券日报 / Nature Biotechnology 今天的10条新闻，涵盖了从基因疗法的监管突破到口服抗真菌药的III期成功，从细胞治疗的孤儿药认定到医保支付的体系创新——罕见病领域的进步正在以"多点开花"的形式加速推进。特别想说的是uniQure AMT-130的故事。从5月被FDA"打回"要求做假手术对照III期，到6月FDA态度大转弯同意加速批准——这一个多月里，不知有多少HD患者家庭经历了从绝望到狂喜的情感过山车。这再次证明了一件事：在罕见病领域，希望永远不要熄灭。你永远不知道下一个转角处，会有怎样的惊喜等着你。还有一周，第三届中国罕见病科研大会就将在上海开幕。22个专场、80+讲者——这将是一次罕见病"产学研医患"各方力量的集中展示。我们会在后续报道中为大家带来大会的一手资讯。愿每一位读到这里的你，无论你是病友、家属、医生还是研究者，都能从今天的新闻中获得一份前进的力量。路很长，但我们在一起。每一条生命都值得全力以赴。扫码回复【入群】获取联系方式和入群方式，更多前沿资讯等你解锁声明：我不是医生，以上内容仅为信息分享，不构成任何医疗建议。具体治疗方案请与您的主治医生沟通，遵医嘱治疗。 💡 加入我们，抱团取暖如果你也想加入全国罕见病交流群，获取最新信息找到病友，扫描下面的二维码，或者加我微信（skyle1106）添加备注加群+罕见病名，拉你进群。文章中所有讯息来自网络公开查证如有错漏，欢迎补充 ⬅️长按二维码关注公众号获取更多罕见病资讯

100 项与 Olorofim 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15245

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
侵袭性真菌感染	申请上市	美国	F2G Ltd.	-
侵袭性曲霉菌病	临床3期	美国	F2G Ltd.	2022-03-31
侵袭性曲霉菌病	临床3期	中国	F2G Ltd.	2022-03-31
侵袭性曲霉菌病	临床3期	日本	F2G Ltd.	2022-03-31
侵袭性曲霉菌病	临床3期	澳大利亚	F2G Ltd.	2022-03-31
侵袭性曲霉菌病	临床3期	比利时	F2G Ltd.	2022-03-31
侵袭性曲霉菌病	临床3期	巴西	F2G Ltd.	2022-03-31
侵袭性曲霉菌病	临床3期	加拿大	F2G Ltd.	2022-03-31
侵袭性曲霉菌病	临床3期	法国	F2G Ltd.	2022-03-31
侵袭性曲霉菌病	临床3期	德国	F2G Ltd.	2022-03-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02730442 \| NCT04171739 \| NCT03340597 \| NCT02737371 \| NCT03583164 \| NCT02680808 (Pubmed \| Antimicrob Agents Chemother)	临床1期	-	96	Olorofim	鑰膚鏇憲糧膚襯廠艱憲(選顧齋獵鏇襯壓壓艱鏇) = 鏇繭積窪鏇膚艱構膚憲觸簾製鑰鬱夢夢積淵構 (憲壓淵醖齋鹽選範網顧 ) 更多	积极	2026-06-03
NCT03583164 (Pubmed \| J Antimicrob Chemother)	临床2期	侵袭性真菌感染	105	Olorofim with concomitant azoles	製膚獵簾網衊範壓夢淵(遞齋選獵醖糧獵窪鬱觸) = 廠積構觸廠醖襯選襯鹹膚簾網顧願淵遞憲夢襯 (窪醖範壓淵鹹構廠遞選 )	积极	2026-03-04
NCT03583164 (Pubmed \| J Antimicrob Chemother)	临床2期	侵袭性真菌感染	105	Olorofim without concomitant azoles	鏇艱齋觸夢淵簾襯鹽餘(遞簾醖獵繭構鬱膚積淵) = 觸範蓋鑰構膚繭構憲壓範積醖鏇襯艱憲顧襯繭 (範鏇願衊襯簾繭憲衊齋 )	积极	2026-03-04
NCT03583164 (Pubmed \| Lancet Infect Dis)	临床2期	侵袭性真菌感染	204	Olorofim	鹽蓋鹹衊網獵築積鑰範(顧鏇襯鏇鹽鹹醖製壓選) = 憲繭醖鑰窪蓋艱襯糧蓋憲繭鹽遞遞糧網網願餘 (衊築膚襯醖糧選夢簾顧 ) 更多	积极	2025-11-01
NCT03583164 (Study 32 \| FORMULA-OLS, CTgov)	临床2期	侵袭性真菌感染	203	Olorofim	築築壓襯淵構觸獵築憲 = 鬱範顧構餘窪顧構築醖選願遞選淵積願觸簾衊 (構窪願簾夢顧憲壓鏇壓, 淵衊淵鹹願蓋構獵壓鏇 ~ 衊鬱窪網遞獵鑰餘選壓) 更多	-	2024-07-10
NCT03583164 (Study 32, GlobeNewswire) 人工标引	临床2期	侵袭性真菌感染	203	Olorofim	夢鑰獵選鑰構鹹範願選(鬱簾築醖糧築齋積壓築) = 醖壓膚餘艱憲遞鹽醖襯鏇窪淵鏇繭艱遞糧夢鏇 (積築淵鏇範艱鬱憲範觸 ) 更多	积极	2023-10-31
NCT03583164 (Study 32 \| FORMULA-OLS, GlobeNewswire) 人工标引	临床2期	侵袭性真菌感染	100	Olorofim	積簾憲願膚齋築遞夢夢(鬱構鏇餘夢鹹窪築網糧) = 齋鹽蓋夢積範製憲衊夢齋鬱糧鑰鏇衊蓋淵齋願 (齋衊鏇製淵夢衊簾鑰襯 ) 更多	积极	2022-10-21